Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC).
Feng Zhang(Hebei Medical University), Shukui Qin(81th Hospital of PLA), Zhenggang Ren(Ministry of Education of the People's Republic of China), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianping Xiong(Nanchang University), Chunyi Hao(Peking University), Yuxian Bai(Harbin Medical University), Tao Zhang(Wuhan Union Hospital), Jun Wang(South China Agricultural University), Juan Zhang(BeiGene (China)), Zhendong Chen(Anhui Medical University), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Yajin Chen(Sun Yat-sen University), Cong Fei(New York University), Zhiqiang Meng(Shanghai Medical College of Fudan University), Liu Yang(China-Japan Friendship Hospital), Yabing Guo(Nanfang Hospital), Weijia Fang(Zhejiang Cancer Hospital), Xikun Wu(BeiGene (China)), Yu Fan(BeiGene (China))
Cited by 4
Related Papers
Graphene and graphene oxide: biofunctionalization and applications in biotechnology
|Trends in biotechnology|2011|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k